Principal Financial Group Inc. cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 35.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 238,605 shares of the medical equipment provider's stock after selling 129,130 shares during the period. Principal Financial Group Inc. owned about 0.34% of Lantheus worth $26,187,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of LNTH. Janus Henderson Group PLC raised its stake in shares of Lantheus by 7.7% in the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider's stock worth $393,844,000 after acquiring an additional 257,022 shares during the last quarter. Farallon Capital Management LLC increased its holdings in shares of Lantheus by 53.7% in the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider's stock valued at $182,999,000 after purchasing an additional 796,000 shares in the last quarter. Geode Capital Management LLC raised its position in Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock worth $184,798,000 after purchasing an additional 32,551 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Lantheus by 1.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider's stock worth $99,525,000 after buying an additional 19,071 shares in the last quarter. Finally, Swedbank AB boosted its position in Lantheus by 21.1% in the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider's stock valued at $79,266,000 after buying an additional 125,843 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.
Lantheus Stock Up 0.3 %
Lantheus stock traded up $0.29 during midday trading on Wednesday, hitting $91.30. 225,431 shares of the stock were exchanged, compared to its average volume of 1,014,194. The stock has a market capitalization of $6.35 billion, a PE ratio of 15.19 and a beta of 0.45. The company has a fifty day simple moving average of $95.36 and a two-hundred day simple moving average of $98.60. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89.
Wall Street Analyst Weigh In
LNTH has been the subject of a number of recent research reports. Redburn Atlantic started coverage on Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price for the company. The Goldman Sachs Group started coverage on Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective for the company. JMP Securities reduced their target price on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research note on Thursday, November 7th. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Finally, Truist Financial restated a "buy" rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $131.86.
Read Our Latest Stock Analysis on LNTH
Lantheus Company Profile
(
Free Report)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Further Reading
Before you consider Lantheus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.
While Lantheus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
